The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO 2017 | The JAVELIN 100 study: a trial to improve lung cancer treatment
Martin Reck, MD, PhD, from the Lung Clinic Grosshansdorf, Grosshansdorf, Germany talks to us about the JAVELIN lung 100 study (NCT02576574), an ongoing Phase III clinical trial which compares the efficacy of avelumab against platinum-based chemotherapy in the treatment of patients with non-small cell lung cancer. Prof. Reck discusses how the trial is being conducted and the ways in which the trial has evolved, and explains how patients may benefit from its data. This interview was recorded at the 2017 European Society for Medical Oncology (ESMO) held in Madrid, Spain.
